Hypha’s newsletter for Q4 2017 focusses on the selective production of N-oxide metabolites, especially relevant where there is potential for… read more →

This quarter we look at interesting off-target activity of some drug metabolites, using the metabolism of valsartan to 4-hydroxyvaleryl-valsartan as… read more →

Scientists in the AgChem industry often need to access metabolites of pesticides and herbicides to meet regulatory requirements. For more… read more →

We will be participating in the 21st North American ISSX meeting taking place in Providence, Rhode Island from September 24th… read more →

We are pleased to announce that the French Ministry of Higher Education, Research and Innovation has granted Hypha the “Crédit… read more →

This issue of Hypha’s newsletter focusses on accessing the major circulating and excretory metabolites of the drug lorcaserin. In particular… read more →

Hypha’s Head of Biochemistry, Antonio De Riso is part of a team who presented work on 2DCOS Analysis of Metabolic… read more →

A cell-free kit of cytochrome P450 enzymes and ferredoxin /ferredoxin reductase partners, termed PolyCYPsTM, is being developed for generating scalable… read more →

Ingenol disoxate is a chemically-stable drug developed by LEO Pharma, effective at treating actinic keratosis topically and currently in Phase… read more →

Interested in solving problems associated with accessing and identifying drug metabolites? Register now for a 30 min webinar given by… read more →